INSULIN-LIKE GROWTH FACTOR-I THERAPY IN DIABETES - PHYSIOLOGICAL-BASIS, CLINICAL BENEFITS, AND RISKS

被引:63
作者
KOLACZYNSKI, JW [1 ]
CARO, JF [1 ]
机构
[1] THOMAS JEFFERSON UNIV, JEFFERSON MED COLL,DEPT MED,COLL BLDG,SUITE 821, 1025 WALNUT ST, PHILADELPHIA, PA 19107 USA
关键词
D O I
10.7326/0003-4819-120-1-199401010-00009
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Purpose: To review the effects of insulin-like growth factor-1 (IGF-1) and to discuss the clinical benefits and risks of using it in patients with diabetes. Data Sources: Recent publications identified through a MEDLINE search using relevant keywords. Study Selection: Selected studies on the metabolic effects and kinetic mechanisms of in vitro IGF-1 and existing literature on the effects of IGF-1 on glucose and lipid metabolism in vivo with special emphasis on data from humans. Data Synthesis: The substantial stimulatory effect of IGF-1 on glucose uptake suggests that, in selected clinical situations, the drug may be an alternative to standard treatment of diabetes. Metabolic control in patients with extreme insulin resistance is improved after using IGF-1. Moreover, patients with type II (non-insulin-dependent) diabetes who receive IGF-1 have improved glucose tolerance and decreased hyperinsulinemia and hypertriglyceridemia. The complications associated with long-term administration of IGF-1 are unknown but might include the progression of certain neoplasms and diabetic complications, such as nephropathy and retinopathy. Conclusions: Insulin-like growth factor-1 may be a useful adjunct for treatment of diabetes and may even be the drug of choice in some patients with extreme insulin resistance who have metabolic emergencies. However, further data are needed to evaluate the risks and benefits of IGF-1 use in diabetes and in other states associated with impaired insulin action.
引用
收藏
页码:47 / 55
页数:9
相关论文
共 118 条
[1]  
ABBOTT AM, 1992, J BIOL CHEM, V267, P10759
[2]   THE GENE ENCODING HUMAN LOW-MOLECULAR WEIGHT INSULIN-LIKE GROWTH-FACTOR BINDING-PROTEIN (IGF-BP25) - REGIONAL LOCALIZATION TO 7P12-P13 AND DESCRIPTION OF A DNA POLYMORPHISM [J].
ALITALO, T ;
KONTULA, K ;
KOISTINEN, R ;
AALTOSETALA, K ;
JULKUNEN, M ;
JANNE, OA ;
SEPPALA, M ;
DELACHAPELLE, A .
HUMAN GENETICS, 1989, 83 (04) :335-338
[3]   INSULIN DIFFERENTIALLY ALTERS TRANSCAPILLARY MOVEMENT OF INTRAVASCULAR IGFBP-1, IGFBP-2 AND ENDOTHELIAL-CELL IGF-BINDING PROTEINS IN THE RAT-HEART [J].
BAR, RS ;
BOES, M ;
CLEMMONS, DR ;
BUSBY, WH ;
SANDRA, A ;
DAKE, BL ;
BOOTH, BA .
ENDOCRINOLOGY, 1990, 127 (01) :497-499
[4]  
BASERGA R, 1993, IN PRESS MOL ONCOLOG
[5]   STRUCTURE OF THE MR 140,000 GROWTH HORMONE-DEPENDENT INSULIN-LIKE GROWTH-FACTOR BINDING-PROTEIN COMPLEX - DETERMINATION BY RECONSTITUTION AND AFFINITY-LABELING [J].
BAXTER, RC ;
MARTIN, JL .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (18) :6898-6902
[6]   RADIOIMMUNOASSAY OF GROWTH-HORMONE DEPENDENT INSULIN-LIKE GROWTH-FACTOR BINDING-PROTEIN IN HUMAN-PLASMA [J].
BAXTER, RC ;
MARTIN, JL .
JOURNAL OF CLINICAL INVESTIGATION, 1986, 78 (06) :1504-1512
[7]  
BINOUX M, 1991, ACTA ENDOCRINOL-COP, V124, P41
[8]   INSULIN-LIKE GROWTH-FACTOR (IGF) AND IGF-BINDING PROTEINS - COMPARISON OF HUMAN-SERUM AND LYMPH [J].
BINOUX, M ;
HOSSENLOPP, P .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1988, 67 (03) :509-514
[9]   DIVERSE EFFECTS OF INSULIN-LIKE GROWTH-FACTOR I ON GLUCOSE, LIPID, AND AMINO-ACID-METABOLISM [J].
BOULWARE, SD ;
TAMBORLANE, WV ;
MATTHEWS, LS ;
SHERWIN, RS .
AMERICAN JOURNAL OF PHYSIOLOGY, 1992, 262 (01) :E130-E133
[10]   CLONING, CHARACTERIZATION, AND EXPRESSION OF A HUMAN INSULIN-LIKE GROWTH-FACTOR BINDING-PROTEIN [J].
BREWER, MT ;
STETLER, GL ;
SQUIRES, CH ;
THOMPSON, RC ;
BUSBY, WH ;
CLEMMONS, DR .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1988, 152 (03) :1289-1297